Bausch Health Companies Inc. BHC

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Bausch Health Companies Inc. ("we", "us", "our", the "Company" or "Bausch Health") is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology ("GI"), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter ("OTC") products and aesthetic medical devices and, through our approximately 88% ownership of Bausch + Lomb Corporation ("Bausch + Lomb" or "B+L"), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. The Company's products are marketed directly or indirectly in approximately 90 countries.

Last close 6.44 2026-10-23
Market cap $2.41B 2026-06-30 share count
52-week range 4.33 - 8.00

Valuation FY2025 figures against the last close

P/S0.2x
P/E15.3x
P/FCF2.4x
EV/EBITDA10.8x
Dividend yield—
Diluted EPS0.42

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $10.27B$9.62B$8.76B$8.12B$8.43B$8.03B$8.60B$8.38B$8.72B$9.67B
Cost of revenue ————————$2.51B$2.57B
Gross profit ————————$6.22B$7.10B
SG&A $3.44B$3.30B$2.92B$2.62B$2.62B$2.37B$2.55B$2.47B$2.58B$2.81B
Total operating expenses $8.45B$8.08B$7.79B$7.67B$7.98B$7.35B$8.80B$10.76B$8.62B$10.24B
Operating income $1.81B$1.55B$963.0M$454.0M$450.0M$676.0M-$203.0M-$2.38B$102.0M-$566.0M
Pre-tax income $367.0M$167.0M-$390.0M-$129.0M-$1.02B-$934.0M-$1.84B-$4.15B-$1.74B-$2.44B
Income tax $247.0M$239.0M$221.0M$83.0M$87.0M$375.0M$54.0M$10.0M$4.14B$27.0M
Net income $157.0M-$46.0M-$592.0M-$225.0M-$948.0M-$560.0M-$1.79B-$4.14B$2.40B-$2.41B
EPS, basic 0.42-0.13-1.62-0.62-2.64-1.58-5.08-11.816.86-6.94
EPS, diluted 0.42-0.13-1.62-0.62-2.64-1.58-5.08-11.816.83-6.94
Shares, diluted (wtd. avg.) 375.0M368.0M364.9M362.0M358.9M355.0M352.1M351.3M351.8M347.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $1.31B$1.18B$947.0M$591.0M$2.12B$1.82B$3.24B$721.0M$797.0M$542.0M
Receivables $2.35B$2.14B$2.00B$1.79B$1.77B$1.58B$1.84B$1.86B$2.13B$2.52B
Inventory $1.63B$1.59B$1.54B$1.09B$993.0M$1.09B$1.11B$934.0M$1.05B$1.06B
Total current assets $6.16B$5.77B$5.60B$4.25B$5.61B$5.34B$6.97B$4.21B$4.75B$5.08B
Property, plant and equipment $2.07B$1.78B$1.71B$1.60B$1.60B$1.57B$1.47B$1.35B$1.40B$1.31B
Goodwill $11.27B$11.09B$11.18B$11.55B$12.46B$13.04B$13.13B$13.14B$15.59B$15.79B
Other intangibles $4.64B$5.55B$6.46B$5.80B$6.95B$8.45B$10.20B$12.00B$15.21B$18.88B
Total assets $26.37B$26.52B$27.35B$25.69B$29.20B$31.20B$33.86B$32.49B$37.50B$43.53B
Accounts payable $600.0M$589.0M$719.0M$521.0M$407.0M$337.0M$503.0M$411.0M$365.0M$324.0M
Short-term debt $225.0M$2.67B$450.0M$432.0M$0$0$1.23B$228.0M$209.0M$1.0M
Total current liabilities $4.18B$6.75B$4.30B$3.94B$5.20B$4.91B$6.25B$3.84B$4.27B$3.61B
Long-term debt $20.59B$18.94B$21.94B$20.33B$22.65B$23.93B$24.66B$24.08B$25.23B$29.84B
Total liabilities $25.99B$26.84B$27.43B$25.43B$29.24B$30.59B$32.73B$29.68B$31.55B$40.27B
Retained earnings -$9.67B-$9.82B-$9.78B-$9.19B-$8.96B-$8.01B-$7.45B-$5.66B-$2.73B-$5.13B
Total equity -$554.0M-$1.28B-$82.0M$260.0M-$34.0M$605.0M$1.14B$2.81B$5.94B$3.26B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.40B$1.60B$1.03B-$728.0M$1.43B$1.11B$1.50B$1.50B$2.29B$2.09B
Depreciation and amortisation $207.0M$190.0M$187.0M$179.0M$177.0M$180.0M$178.0M$175.0M$168.0M$193.0M
Stock-based compensation $216.0M$150.0M$132.0M$126.0M$128.0M$105.0M$102.0M$87.0M$87.0M$165.0M
Capital expenditure $397.0M$337.0M$215.0M$218.0M$269.0M$302.0M$270.0M$157.0M$171.0M$235.0M
Investing cash flow -$595.0M-$454.0M-$2.15B-$303.0M$409.0M-$261.0M-$419.0M-$196.0M$2.89B-$125.0M
Financing cash flow -$742.0M-$868.0M$1.48B-$474.0M-$1.51B-$2.29B$1.44B-$1.35B-$4.96B-$1.96B
Buybacks ————————$0$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-013816.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -5B 0 5B 10B 15B Revenue, FY2016: 9.7B Gross profit, FY2016: 7.1B Net income, FY2016: -2.4B Revenue, FY2017: 8.7B Gross profit, FY2017: 6.2B Net income, FY2017: 2.4B Revenue, FY2018: 8.4B Net income, FY2018: -4.1B Revenue, FY2019: 8.6B Net income, FY2019: -1.8B Revenue, FY2020: 8B Net income, FY2020: -560M Revenue, FY2021: 8.4B Net income, FY2021: -948M Revenue, FY2022: 8.1B Net income, FY2022: -225M Revenue, FY2023: 8.8B Net income, FY2023: -592M Revenue, FY2024: 9.6B Net income, FY2024: -46M Revenue, FY2025: 10.3B Net income, FY2025: 157M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $9.67B $8.72B $8.38B $8.60B $8.03B $8.43B $8.12B $8.76B $9.62B $10.27B
Gross profit $7.10B $6.22B — — — — — — — —
Net income -$2.41B $2.40B -$4.14B -$1.79B -$560.0M -$948.0M -$225.0M -$592.0M -$46.0M $157.0M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%